Anti-lipoprotein lipase antibodies: A new player in the complex atherosclerotic process in systemic lupus erythematosus?

Arthritis and Rheumatism

Volumn 50, Issue 11, 2004, Pages 3610-3615

  De Carvalho, Jozélio Freire ^a   Borba, Eduardo Ferreira ^a   Viana, Vilma Santos Trindade ^a   Bueno, Cleonice ^a   Leon, Elaine Pires ^a   Bonfá, Eloísa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANTIBODY SCREENING; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPOPROTEINEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARTERIOSCLEROSIS; AUTOANTIBODIES; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COMPLEMENT SYSTEM PROTEINS; DNA; FEMALE; HUMANS; LIPOPROTEIN LIPASE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 8444224272     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20630     Document Type: Article

References (51)

1. Korn ED. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem 1955;215:1-14.
2. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw Hill; 1995. p. 1913-32.
3. Miller AL, Smith LC. Activation of lipoprotein lipase by apolipoprotein glutamic acid: formation of a stable surface film. J Biol Chem 1973;248:3359-62.
4. Havel RJ, Fielding CJ, Olivecrona T, Shore VG, Fielding PE, Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources. Biochemistry 1973;12:1828-33.
5. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972;46:1265-73.
6. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000;43:1033-40.
7. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002;46:2957-63.
8. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:146-50.
9. Tanaka Y, Saito K, Shirakawa F, Ota T, Suzuki H, Eto S, et al. Production of B cell-stimulating factors by B cells in patients of systemic lupus erythematosus. J Immunol 1988;141:3043-9.
10. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus: an indicator of disease activity? Clin Exp Immunol 1992;90:106-10.
11. Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982;25:396-400.
12. Morrow WJ, Isenberg DA, Parry HF, Snaith ML. C-reactive protein in sera from patients with systemic lupus erythematosus. J Rheumatol 1981;8:599-604.
13. Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982;8:91-103.
14. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997;6:533-9.
15. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatol 1995;22:1259-64.
16. Stein Y, Stein O. Lipoprotein lipase and atherosclerosis. Atherosclerosis 2003;170:1-9.
17. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
18. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
19. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.
20. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
21. Semb H, Peterson J, Tavernier J, Olivecrona T. Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 1987;262:8390-4.
22. Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985;135:3969-71.
23. Ehnolm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin lipases. Arteriosclerosis 1982;2:69-73.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
26. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
27. Kurata N, Tan EM. Identification of antibody to nuclear acidic antigens by counterimmunoelectrophoresis. Arthritis Rheum 1976;19:574-80.
28. Elkon KB, Culhane L. Partial immunochemical characterization of the Ro and La proteins using antibodies from patients with the sicca syndrome and lupus erythematosus. J Immunol 1984;132:2350-6.
29. Tan EM, Peebles C. Quantitation of antibodies to Sm antigen and nuclear ribonucleoprotein by hemagglutination. In: Rose NR, Friedman H, editors. Manual of clinical immunology. 2nd ed. Washington: American Society of Microbiology; 1980. p. 866-70.
30. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987;46:1-6.
31. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983;29:1075-80.
32. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-80.
33. Warnick GR, Cheung NC, Albers JJ. Comparison of current methods for high density lipoprotein cholesterol quantification. Clin Chem 1979;25:596-604.
34. Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
35. Okamoto Y, Tominaga K, Uemura S, Matsuoka H, Tsujii T, Nakano H. Hypertriglyceridemia caused by the autoantibody to lipases for plasma lipoproteins: a case report. J Atheroscler Thromb 1995;2:66-9.
36. Yoshimura T, Ito M, Sakoda Y, Kobori S, Okamura H. Rare cases of autoimmune hyperchylomicronemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1998;76:49-51.
37. Pruneta V, Moulin P, Labrousse F, Bondon PJ, Ponsin G, Berthezene F. Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy. J Clin Endocrinol Metabol 1997;82:791-6.
38. Eckel RH. Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989;320:1060-8.
39. Vilella E, Joven J, Fernandez M, Vilaro S, Brunzell JD, Olivecrona T, et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 1993;34:1555-64.
40. Clee SM, Bissada N, Miao L, Marais AD, Henderson HE, Steures P, et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000;41:521-31.
41. Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in atherosclerosis? FEBS Lett 1999;462:1-6.
42. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003;48:2533-40.
43. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
44. Ward MM, Pisetsky DS, Christenson VD. Anti-double stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements. J Rheumatol 1989;16:609-13.
45. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother 2003;57:282-6.
46. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999;99:1997-2002.
47. Meroni PL, Raschi E, Camera M, Testoni C, Nicoletti F, Ticani A, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000;15:237-40.
48. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation 1998;98:1108-15.
49. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;2:74-80.
50. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
51. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-92.